A Phase 1, Open-label Study of SNX‑5422 and Ibrutinib in Chronic Lymphocytic Leukemia Subjects With a Mutation in Bruton's Tyrosine Kinase
Phase of Trial: Phase I
Latest Information Update: 28 Apr 2017
At a glance
- Drugs Ibrutinib (Primary) ; SNX 5422 (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- Sponsors Esanex
- 13 Feb 2017 Status changed from not yet recruiting to recruiting.
- 22 Nov 2016 Planned End Date changed from 1 Jan 2018 to 1 Oct 2018.
- 22 Nov 2016 Planned primary completion date changed from 1 Oct 2017 to 1 Mar 2018.